{"id":1703,"date":"2023-06-25T17:32:51","date_gmt":"2023-06-25T17:32:51","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/carmustine\/"},"modified":"2023-06-25T19:39:31","modified_gmt":"2023-06-25T19:39:31","slug":"carmustine","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/carmustine\/","title":{"rendered":"Carmustine"},"content":{"rendered":"

<\/p>\n

Carmustine<\/h1>\n

CLINICAL USE<\/h3>\n

Alkylating agent:<\/p>\n

  • Myeloma, lymphoma and brain tumours
    \n

    DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

    150\u2013200 mg\/m2 as a single dose or 75\u2013100 mg\/m2 on 2 consecutive days every 6 weeks Implants: 7.7mg, maximum 8 implants<\/p>\n

    PHARMACOKINETICS<\/h3>\n<\/li>\n
  • Molecular weight                           :214.1<\/li>\n
  • %Protein binding                           :77<\/li>\n
  • %Excreted unchanged in urine     : 60\u201370<\/li>\n
  • Volume of distribution (L\/kg)       :3.25<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :22 minutes\/\u2013
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           : Dose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :Not dialysed. Dose as in normal renal function<\/li>\n
  • HD                     :Not dialysed. Dose as in normal renal function<\/li>\n
  • HDF\/high flux   :Unknown dialysability. Dose as in normal renal function<\/li>\n
  • CAV\/VVHD      :Not dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugsNone known<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n<\/li>\n
  • 3 mL of the supplied diluent (absolute ethanol) then add 27 mL of sterile water for injection<\/li>\n
  • This solution may be further diluted with sodium chloride 0.9% or glucose 5% for injection
    \n

    Route<\/h4>\n

    IV<\/p>\n

    Rate of Administration<\/h4>\n<\/li>\n
  • Administer by IV drip over a period of 1\u20132 hours
    \n

    Comments<\/h4>\n<\/li>\n
  • Therapy should not be repeated before 6 weeks<\/li>\n
  • Can further dilute the reconstituted solution with 500 mL of sodium chloride 0.9% or glucose 5%
    \n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • Renal abnormalities, e.g. a decrease in kidney size: progressive azotaemia and renal failure have been reported in patients receiving large cumulative doses after prolonged therapy<\/li>\n
  • Partially metabolised to active species by liver microsomal enzymes, which have a long T\u00bd. It is thought that the antineoplastic activity may be due to metabolites. Approximately 30% of a dose is excreted in the urine after 24 hours, and 60\u201370% of the total dose after 96 hours. About 10% is excreted as respiratory CO2. Terminal half-life of the metabolites are about 1 hour.<\/li>\n","protected":false},"excerpt":{"rendered":"

    Carmustine CLINICAL USE Alkylating agent: Myeloma, lymphoma and brain tumours<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1703","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1703"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1703\/revisions"}],"predecessor-version":[{"id":2824,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1703\/revisions\/2824"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}